Mandate

Vinge advises the Swedish state in connection with the recapitalization of SAS

Vinge advises the Swedish state in connection with the recapitalization of SAS. The recapitalization plan, which includes State aid that has been approved by the EU Commission, restores SAS’ equity by SEK 14.25 billion and secures approximately SEK 12 billion of new funding.

The recapitalization plan consists of a directed issue of shares to the Swedish and Danish states, a rights issue of shares to existing shareholders, two directed issues of hybrid notes, of which one is directed to the Swedish and Danish states and one is directed to the Danish state, as well as conversion of existing hybrid notes into shares and of existing bonds into new hybrid notes or shares. The conversion of debt instruments aims at distributing the economic burden of the company’s recapitalization. In aggregate, the Swedish state provides SAS with SEK 5 billion in connection with the recapitalization of the company.

Vinge’s team consisted of Charlotte Levin, Erik Sjöman, Martin Johansson, Amanda Knutsson, Hedvig Josefson and Julia Hirschberg.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026